acute basophilic leukemia
MONDO:0019458
A rare acute myeloid leukemia in which the immature cells differentiate towards basophils.
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
MONDO disease family
Recruiting studies by city
Trial status
Trial phase
Study start year
Investigated drug interventions
Acute basophilic leukemia
Acute basophilic leukemia (ABL) is a very rare & clinically aggressive subtype of acute myeloid leukemia (AML) designated by the WHO as a distinct entity within the subcategory of AML, Not Otherwise Specified (NOS), which accounts for roughly 4-5% of all "acute non-lymphocytic" cases of leukemia. ABL can be either primary (sporadic) or secondary to an existing bone marrow neoplasm (commonly CML or AML with BCR-ABL1). In either case, the disease is characterized by rapid proliferation of abnormal basophils & immature blasts in the bone marrow and peripheral blood. This process interferes with normal blood cell production, giving rise to classic symptoms of AML & ultimately bone marrow failure. Given the role of basophils in coordinating histamine release during inflammatory reactions, those with ABL also typically experience symptoms of hyper-histaminemia which can manifest cutaneously & within the gastrointestinal tract.
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Drugs being studied
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.